lenzilumab

Home
Ligands
lenzilumab

GtoPdb Ligand ID: 8935

Synonyms: KB-003 | KB003

Comment: Lenzilumab is a fully human IgG1κ moncolonal antibody targeting granulocyte-macrophage colony-stimulating factor (GM-CSF), being investigated for its immunomodulatory potential.
Peptide sequences for this antibody are available from its IMGT/mAb-DB record.
BLAST peptide searches using the variable regions of the heavy and light chains of the antibody reveal exact matches with sequences submitted with patent US8075885 B2 [1].

References
1. Bebbington CR, Yarranton GT. (2011) Methods of treating heart failure using an anti-GM-CSF antibody. Patent number: US8075885 B2. Assignee: Kalobios Pharmaceuticals, Inc.. Priority date: 01/12/2015. Publication date: 13/12/2011.
2. Hamilton JA. (2015) GM-CSF as a target in inflammatory/autoimmune disease: current evidence and future therapeutic potential. Expert Rev Clin Immunol, 11 (4): 457-65. [PMID:25748625]
3. Padron E, Painter JS, Kunigal S, Mailloux AW, McGraw K, McDaniel JM, Kim E, Bebbington C, Baer M, Yarranton G et al.. (2013) GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia. Blood, 121 (25): 5068-77. [PMID:23632888]

References

1. Bebbington CR, Yarranton GT. (2011)
Methods of treating heart failure using an anti-GM-CSF antibody.
Patent number: US8075885 B2. Assignee: Kalobios Pharmaceuticals, Inc.. Priority date: 01/12/2015. Publication date: 13/12/2011.

2. Hamilton JA. (2015)
GM-CSF as a target in inflammatory/autoimmune disease: current evidence and future therapeutic potential.
Expert Rev Clin Immunol, 11 (4): 457-65. [PMID:25748625]

3. Padron E, Painter JS, Kunigal S, Mailloux AW, McGraw K, McDaniel JM, Kim E, Bebbington C, Baer M, Yarranton G et al.. (2013)
GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia.
Blood, 121 (25): 5068-77. [PMID:23632888]